An FDA panel backed Grail’s Galleri test. But the Medicare money the business depends on is far from guaranteed.

© Grail Inc.

The real opportunity is pill-form peptides that could hit big pharma’s most profitable franchises.

© Getty Images

With the Food and Drug Administration’s hard-liners gone, investors are rushing back into rare-disease bets.

© Maansi Srivastava/The Washington Post/Getty Images